Assenagon Asset Management S.A. Raises Position in Gilead Sciences, Inc. $GILD

Key Points

• Assenagon Asset Management significantly increased its holdings in Gilead Sciences by 265.0% in Q2, now owning approximately $146.33 million worth of stock.
• Analysts have a consensus rating of "Moderate Buy" for Gilead Sciences, with several firms recently upgrading their price targets.
• Gilead Sciences announced a quarterly dividend of $0.79 per share, with an annual yield of 2.8%, set to be paid on September 29th.

Assenagon Asset Management S.A. lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 265.0% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,319,796 shares of the biopharmaceutical company's stock after buying an additional 958,202 shares during the period. Assenagon Asset Management S.A. owned about 0.11% of Gilead Sciences worth $146,326,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of GILD. Price T Rowe Associates Inc. MD increased its holdings in shares of Gilead Sciences by 314.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company's stock worth $1,647,484,000 after buying an additional 11,156,382 shares in the last quarter. Nuveen LLC acquired a new stake in Gilead Sciences in the first quarter valued at $620,415,000. GAMMA Investing LLC increased its holdings in Gilead Sciences by 13,891.1% in the first quarter. GAMMA Investing LLC now owns 2,550,298 shares of the biopharmaceutical company's stock valued at $285,761,000 after purchasing an additional 2,532,070 shares during the period. Kingstone Capital Partners Texas LLC acquired a new stake in Gilead Sciences in the second quarter valued at $238,083,000. Finally, Los Angeles Capital Management LLC increased its holdings in Gilead Sciences by 422.6% in the first quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company's stock valued at $282,706,000 after purchasing an additional 2,040,261 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Down 1.4%

Shares of GILD traded down $1.60 on Monday, reaching $112.49. The company's stock had a trading volume of 3,744,591 shares, compared to its average volume of 8,069,200. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a twelve month low of $81.83 and a twelve month high of $121.83. The stock has a market capitalization of $139.58 billion, a PE ratio of 22.41, a PEG ratio of 0.77 and a beta of 0.36. The firm has a fifty day moving average of $114.10 and a 200-day moving average of $109.98.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. The company had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm's revenue was up 1.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be paid a $0.79 dividend. The ex-dividend date is Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.8%. Gilead Sciences's dividend payout ratio (DPR) is 62.95%.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on GILD. Truist Financial upgraded Gilead Sciences from a "hold" rating to a "buy" rating and increased their price objective for the company from $108.00 to $127.00 in a report on Friday, August 8th. UBS Group increased their price objective on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a report on Friday, August 8th. Royal Bank Of Canada upped their price target on shares of Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a research report on Friday, August 8th. JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $135.00 to $145.00 and gave the company an "overweight" rating in a research report on Tuesday, September 16th. Finally, Daiwa America raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat, Gilead Sciences presently has an average rating of "Moderate Buy" and a consensus target price of $117.17.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $283,925.00. Following the completion of the sale, the chief financial officer owned 159,555 shares in the company, valued at approximately $18,120,661.35. This trade represents a 1.54% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $340,710.00. Following the completion of the sale, the insider owned 113,193 shares of the company's stock, valued at approximately $12,855,329.01. This trade represents a 2.58% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 82,000 shares of company stock worth $9,390,030. Insiders own 0.27% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.